HK1046925A1 - Mage-a12抗原肽及其用途 - Google Patents

Mage-a12抗原肽及其用途

Info

Publication number
HK1046925A1
HK1046925A1 HK02107155.4A HK02107155A HK1046925A1 HK 1046925 A1 HK1046925 A1 HK 1046925A1 HK 02107155 A HK02107155 A HK 02107155A HK 1046925 A1 HK1046925 A1 HK 1046925A1
Authority
HK
Hong Kong
Prior art keywords
mage
antigenic peptides
antigenic
peptides
Prior art date
Application number
HK02107155.4A
Other languages
English (en)
Inventor
Heidecker Leonora
Van Den Eynde Benoit
Boon-Falleur Thierry
Brasseur Francis
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Publication of HK1046925A1 publication Critical patent/HK1046925A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02107155.4A 1999-10-19 2002-09-27 Mage-a12抗原肽及其用途 HK1046925A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16037499P 1999-10-19 1999-10-19
US17957000P 2000-02-01 2000-02-01
PCT/US2000/028852 WO2001029220A2 (en) 1999-10-19 2000-10-19 Mage-a12 antigenic peptides and uses thereof

Publications (1)

Publication Number Publication Date
HK1046925A1 true HK1046925A1 (zh) 2003-01-30

Family

ID=26856840

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107155.4A HK1046925A1 (zh) 1999-10-19 2002-09-27 Mage-a12抗原肽及其用途

Country Status (8)

Country Link
EP (1) EP1222274A2 (zh)
JP (1) JP2003512057A (zh)
KR (1) KR20020047249A (zh)
CN (1) CN1402782A (zh)
AU (1) AU1335601A (zh)
CA (1) CA2386088A1 (zh)
HK (1) HK1046925A1 (zh)
WO (1) WO2001029220A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
ATE438409T1 (de) 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
EP1456668B1 (en) * 2001-12-05 2007-05-02 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
EP2193804B1 (en) * 2003-11-21 2015-12-23 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
EP2755997B1 (en) * 2011-09-15 2018-07-04 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
KR101851666B1 (ko) 2013-03-08 2018-04-24 다이호야쿠힌고교 가부시키가이샤 신규 ctl 에피토프 5 연결 펩타이드
JP6211093B2 (ja) 2013-10-21 2017-10-11 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5487974A (en) 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
WO1994016713A1 (en) 1993-01-22 1994-08-04 Ludwig Institute For Cancer Research Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5610013A (en) 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5589334A (en) 1994-06-03 1996-12-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules

Also Published As

Publication number Publication date
WO2001029220A3 (en) 2002-03-07
WO2001029220A2 (en) 2001-04-26
KR20020047249A (ko) 2002-06-21
EP1222274A2 (en) 2002-07-17
CA2386088A1 (en) 2001-04-26
CN1402782A (zh) 2003-03-12
AU1335601A (en) 2001-04-30
JP2003512057A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
EP1064022A4 (en) HLA BINDING PEPTIDES AND THEIR APPLICATIONS
PL346346A1 (en) Cyclic prosaposin-derived peptides and uses thereof
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
PT2275552E (pt) Péptidos antigénicos de neisseria
PL344341A1 (en) Peptides
GB9927332D0 (en) Novel antibody and uses thereof
GB9806806D0 (en) Peptides and uses thereof
EP1173467A4 (en) CHEMOKIN DERIVED SYNTHETIC PEPTIDES
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
HK1046925A1 (zh) Mage-a12抗原肽及其用途
GB9918156D0 (en) Synthetic peptides
HK1051544A1 (en) Novel hev antigenic peptide and methods
GB9918155D0 (en) Proteins and peptides
EP1185558A4 (en) PEPTIDES WITH PREPTID FUNCTIONALITY
EP1197556A4 (en) USEFUL POLYPEPTIDE
EP1194548A4 (en) NOVEL PYRRHOCORICIN-DERIVED PEPTIDES AND METHODS OF IMPLEMENTING THE SAME
GB0026134D0 (en) Peptides and their use
GB9812675D0 (en) Peptides
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
GB9924951D0 (en) Novel polypeptide
IL145527A0 (en) Retro-inverso prosaposin-derived peptides and use thereof
GB9807890D0 (en) Peptides
GB9923893D0 (en) Novel polypeptide
HK1047116A1 (zh) 來自mage的免疫原性肽及其應用